Critical Reviews in Oncology/Hematology 39 (2001) 203 – 218
Role of radiation dosimetry in radioimmunotherapy planning and
treatment dosing
Gerald L. DeNardo
a
*, Malik E. Juweid
b
, Christine A. White
c
,
Gregory A. Wiseman
d
, Sally J. DeNardo
a
a
Room 3100, Hematology /Oncology, Radiodiagnosis and Therapy, Uniersity of California, Dais Medical Center, 1508 Alhambra Bld.,
Sacramento, CA 95816, USA
b
Garden State Cancer Center, Belleille, NJ 07109, USA
c
IDEC Pharmaceuticals Corp, San Diego, CA 92121, USA
d
Mayo Clinic, Rochester, MN 55905, USA
Accepted 12 January 2001
Contents
1. Introduction ............................................... 204
2. Purposes of radiation dosimetry .................................... 205
3. Methods for radiation dosimetry.................................... 206
4. Tracer vs. therapy radiation dosimetry ................................ 207
5. Nonmyeloablative vs. myeloablative therapy ............................. 208
6. Marrow radiation dosimetry ...................................... 209
6.1. Traditional methods ........................................ 209
6.2. Imaging-based methods ...................................... 210
7. Treatment dosing methods ....................................... 210
7.1. Radiation dose (cGy)-based methods .............................. 211
7.2. Radionuclide dose (GBq)-based methods ............................ 211
8. Relationship between radiation dose and toxicity or tumor response ............... 212
9. Regulatory considerations ........................................ 213
Acknowledgements ............................................. 214
References .................................................. 214
Biographies .................................................. 217
Abstract
Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all
www.elsevier.com/locate/critrevonc
* Corresponding author. Tel.: +916-734-3787; fax: +916-451-2857.
E-mail address: gldenardo@ucdavis.edu (G.L. DeNardo).
1040-8428/01/$ - see front matter © 2001 Elsevier Science Ireland Ltd. All rights reserved.
PII:S1040-8428(01)00109-3